Summer 8-7-2018

# Hepatitis C and Risk of Adverse Treatment Outcomes among Patients with HIV and Multidrug-resistant Tuberculosis

Aung Aung
*Georgia State University*

Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses

ABSTRACT

# HEPATITIS C AND RISK OF ADVERSE TREATMENT OUTCOMES AMONG PATIENTS WITH HIV AND MULTIDRUG-RESISTANT TUBERCULOSIS

By

AUNG AUNG

July 19, 2018

## BACKGROUND
Multidrug-resistant (MDR) tuberculosis (TB) is a public health emergency that causes substantial morbidity and mortality. Treatment of MDR-TB requires 9-24 months of second-line regimens, has poor success rates, and frequently results in harmful side effects. Hepatitis C virus (HCV) co-infection is a common comorbidity among patients with MDR-TB/HIV and contributes to acute and chronic liver conditions, potentially increasing the risk of hepatotoxicity and adverse treatment outcomes. The aim of this study was to estimate the association between HCV co-infection and adverse MDR-TB treatment outcomes among patients with MDR-TB and HIV.

## METHODS
We conducted a retrospective cohort study among MDR-TB patients co-infected with HIV receiving clinical care from Médecins Sans Frontières (MSF) in Yangon, Myanmar during 2009-2017. Eligible patients included adults aged ≥18 years who had final MDR-TB treatment outcome and HCV status documented. HCV status was determined by OraQuick® antibody test. Treatment outcome was classified as favorable (cured and treatment completed) or adverse (default, failed, died, not evaluated).

## RESULTS
Among patients with MDR-TB and HIV (n=220), the overall treatment success rate was 65% (95%CI 59 – 71%) and 8% (95%CI 5-12%) had HCV. Co-infection with HCV was not significantly associated with adverse treatment outcome in unadjusted (OR 1.33, 95%CI 0.49 – 3.65) or adjusted analyses (aOR 1.43, 95%CI 0.50 – 4.03).

## CONCLUSION
Whether patients with HIV/HCV co-infection require altered MDR-TB treatment regimens remains an important gap in knowledge. Additional research is needed to determine the relationship between the extent of hepatotoxicity due to HCV co-infection, interaction with second-line TB medications, and risk of poor MDR-TB treatment outcomes among patients with and without HIV.

HEPATITIS C AND RISK OF ADVERSE TREATMENT OUTCOMES AMONG PATIENTS
WITH HIV AND MULTIDRUG-RESISTANT TUBERCULOSIS

by

AUNG AUNG

M.B., B.S. University of Medicine 1 – Yangon

A Thesis Submitted to the Graduate Faculty
of Georgia State University in Partial Fulfillment
of the
Requirements for the Degree

MASTER OF PUBLIC HEALTH

ATLANTA, GEORGIA
30303

APPROVAL PAGE


HEPATITIS C AND RISK OF ADVERSE TREATMENT OUTCOMES AMONG PATIENTS
WITH HIV AND MULTIDRUG-RESISTANT TUBERCULOSIS


by

AUNG AUNG


Approved:


_____Matthew J. Magee, MPH, Ph.D._____
Committee Chair


_____Richard Rothenberg, MD, MPH, FACP_____
Committee Member


_____July 19, 2018_____
Date

3

# ACKNOWLEDGMENTS

Author's Statement Page

       In presenting this thesis as a partial fulfillment of the requirements for an advanced degree from Georgia State University, I agree that the Library of the University shall make it available for inspection and circulation in accordance with its regulations governing materials of this type. I agree that permission to quote from, to copy from, or to publish this thesis may be granted by the author or, in his/her absence, by the professor under whose direction it was written, or in his/her absence, by the Associate Dean, School of Public Health. Such quoting, copying, or publishing must be solely for scholarly purposes and will not involve potential financial gain. It is understood that any copying from or publication of this dissertation which involves potential financial gain will not be allowed without written permission of the author.


               ___Aung Aung____
               Signature of Author

# TABLE OF CONTENTS

# LIST OF TABLES

# LIST OF FIGURES

# CHAPTER I

## INTROUDCTION

### 1.1 Background

The global ambition to end the tuberculosis (TB) epidemic is determined by the End-TB Strategy. This global target is set for 2035 when the End-TB goals state mortality rates should have a 95% reduction compared to 2015, and reduction of TB incidence rate <10 per 100,000 population. To achieve the global End-TB targets, priority indicators are to reach TB treatment coverage and success rate to $\geqslant$ 95% and to reduce case fatality ratio (CFR) to < 5%. Although some progress has been made in achieving global targets, key challenges like multidrug-resistant tuberculosis (MDR-TB) and lack of funding prohibit full realization of these End-TB goals (World Health Organization, 2014).

In 2016 the global TB incidence was estimated at 10.4 million people and accounted for approximately 1.3 million deaths and an additional 0.4 million deaths among HIV-positive people. MDR-TB is a form of TB resistant to at least two of the most potent anti-TB drugs (rifampicin and isoniazid), and the 2016 MDR TB incidence was 490,000 (World Health Organization, 2017c). The global prevalence of hepatitis C virus (HCV) infection was 71 million people in 2015, and almost 400,000 die annually due to chronic HCV infection (World Health Organization, 2017b).

Myanmar is included in 30 high burden countries (HBC) with overlapping TB, MDR-TB and HIV/TB epidemics (World Health Organization, 2015). In Myanmar, the overall incidence of MDR-TB and RR-TB was 13,000 (8,800 – 18,000) in 2016. Among them, only 1,497 MDR/RR-TB cases were started on second-line treatment in 2014, and the success rate was estimated to have 80% (World Health Organization, 2017a). The rate of HCV was 2% among

healthy individuals, and 27% in patients with acute and chronic liver conditions in Myanmar in 2001 (Nakai, Win, Oo, Arakawa, & Abe, 2001).

Treatment of MDR-TB is available, but it requires substantially longer duration (9 – 24 months) with more expensive second-line toxic drugs (Marks et al., 2014) and the treatment is less effective than the treatment of drug-sensitive TB (Micheletti, Kritski, & Braga, 2016). Moreover, there are multiple side-effects of MDR-TB treatment for patients ranging from self-limiting reactions like arthralgia (aching or pain in the joints) and dermatological complications (Yang et al., 2017) to life-threatening toxicities such as nephrotoxicity, cardiotoxicity, and hepatotoxicity (Ramachandran & Swaminathan, 2015). HCV infection frequently results in chronic liver disease with causes persistent liver cell damage leading to cirrhosis and hepatocellular carcinoma. HCV co-infection is common among HIV patients (Platt et al., 2016), and TB patients. The triad of HCV, HIV, and TB promotes the additional risk of drug-induced liver injury during the TB treatment in HIV population (Kwon et al., 2007). Given the increased risk of MDR-TB treatment on hepatotoxicity, HCV co-infection may augment the risk of liver disease during the treatment, leading to a higher chance of adverse MDR-TB treatment outcomes.

MDR-TB treatment success rates are not as favorable as drug-sensitive TB. According to MDR-TB outcome analysis by Falzon et al. (Falzon et al., 2015), the treatment outcome among 23 high TB burden countries has a median success rate of 53% (IQR 40% - 70%). Many factors are associated with adverse treatment outcome particularly HIV co-infection (Farley et al., 2011) and chronic HCV co-infection (Kikvidze & Ikiashvili, 2014). Studies found that drug-induced hepatotoxicity in TB and MDR-TB treatment was associated with HCV co-infection (Lee et al., 2016; Lomtadze et al., 2013). There were also other studies on MDR-TB treatment outcome

10

which suggested that mortality rate during TB treatment was higher among individuals living with HIV (Isaakidis et al., 2015). However, the impact of HCV infection on MDR-TB treatment outcomes in the context of HIV co-infection is still needed to elaborate.

## 1.2 Gap and Purpose of Study

Current knowledge on MDR-TB outcomes among patients with HCV and HIV infection is limited. Improved knowledge regarding the role of HCV in adverse MDR-TB outcome in patients with HIV may inform future clinical HIV-TB guidelines including how to monitor side effects, and risk stratification. Mortality due to MDR-TB is high even with the proper treatment (Chung-Delgado, Guillen-Bravo, Revilla-Montag, & Bernabe-Ortiz, 2015; Gandhi et al., 2012). Even incremental improvements in MDR-TB treatment outcomes may substantially improve clinical care for high HIV/TB burden countries like Myanmar. Therefore, in the cohort of HIV patients with MDR-TB in Myanmar, the aims of our study are to

1) Determine socioeconomic, clinical and laboratory characteristics associated with HCV infection;

2) Determine the association between HCV comorbidity and adverse MDR-TB treatment outcomes.

# CHAPTER II

REVIEW OF LITERATURE

2.1 Multidrug-Resistant Tuberculosis

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) caused by the same mycobacteria organism but molecularly resistant to two of the most potent anti-TB agents, rifampicin and isoniazid. Since anti-TB drugs have been used for decades, drug resistance has been documented in every country where inappropriate practice of anti-TB treatment is present; such as incorrect prescription by healthcare providers, poor quality drugs, and patients' adherence to the treatment (World Health Organization, 2017c). The molecular mechanisms of drug-resistant TB depend on different developments such as the genetic basis of resistance, mutation rate, mutation type and hetero-resistant and preexisting mutants (Gillespie, 2002), which results in different categories of drug resistance including (1) monoresistance – resistant only to one first-line anti-TB drug, (2) polydrug resistance – resistant to more than one first-line anti-TB drug other than isoniazid and rifampicin, (3) multidrug resistance or MDR-TB – resistant to at least both isoniazid and rifampicin, (4) extensive drug resistance or XDR-TB – resistant to fluoroquinolone and at least one of injectable drugs in addition to multidrug resistance, (5) rifampicin resistance or RR-TB – resistant only to rifampicin with or without resistance to other anti-TB drugs (World Health Organization, 2013).

Treatment of MDR-TB is possible, but only 22% of global MDR-TB/RR-TB patients (130,000 of 600,000) received the treatment in 2016 (World Health Organization, 2017c). The MDR-TB treatment requires a long duration ranging 9 – 24 months (World Health Organization, 2016) of expensive antibiotic courses (Kang et al., 2006; Marks et al., 2014; Schnippel et al., 2013), but they are more toxic and less effective (Micheletti et al., 2016) than the drugs used to

treat drug-susceptible TB. In addition, side-effects of MDR-TB treatment affect different systems of the human body – ototoxicity, psychiatric disorder, gastrointestinal disturbance, arthralgia, hepatitis, epileptic seizures and dermatological complications (Torun et al., 2005; Yang et al., 2017). The minor side-effects such as skin reaction, arthralgia, and gastrointestinal upsets are common and easily manageable by symptomatic treatment. However, some severe toxicities such as nephrotoxicity, cardiotoxicity, gastrointestinal toxicity, central nervous system toxicity due to certain drugs are life-threatening (Ramachandran & Swaminathan, 2015). Side-effects were mostly experienced in 37% to 99% of patients receiving treatment (J. C. Brust et al., 2013; Yang et al., 2017) that can lead to sporadic treatment interruption, potentially increasing the risk of poor treatment outcome (Podewils, Gler, Quelapio, & Chen, 2013).

2.2 Outcome of Multidrug-Resistant Tuberculosis treatment

The World Health Organization has classified the treatment outcome for RR-TB/MDR-TB/XDR-TB patients treated using second-line treatment as cured, treatment completed, treatment failed, died, lost to follow-up or not evaluated – defining treatment success as the sum of cured and treatment completed (World Health Organization, 2013). The median success rate of MDR-TB treatment among 23 countries out of 30 high TB burden countries (World Health Organization, 2017a) was 53% (IQR 40 – 70%) (Falzon et al., 2015) a rate that is far below the target set for Global Plan to stop TB 2011 – 2015 in which the treatment success rate among confirmed MDR-TB cases should be ⩾75%. The overview of adverse outcome among high burden countries was 11% (8 – 17) died, 8% (2 – 11) had treatment failure, 13% (8 – 18) were lost to follow up, and 4% (1 – 14) were not evaluated (Falzon et al., 2013).

13

There are different factors associated with MDR-TB treatment success such as being female, improvement on radiological findings (Jain, Desai, Solanki, & Dikshit, 2014), non-HIV patients, sputum smear-negative at baseline, without prior DR-TB (Bastos et al., 2017), use of individualized treatment regimen (Kibret, Moges, Memiah, & Biadgilign, 2017) and use of fluoroquinolone, aminoglycoside, and Group IV MDR-TB drugs (Anderson et al., 2013; Isaakidis et al., 2015). Importantly, adverse treatment outcome is associated with many host-related factors such as male sex, older age, prior TB treatment (Xu et al., 2018), having HIV co-infection, low baseline body weight (i.e., < 45 kg) (Farley et al., 2011), chronic viral hepatitis C co-infection (Kikvidze & Ikiashvili, 2014), lung cavitation at baseline chest X-ray (Ahmad et al., 2015), and resistance to ofloxacin and streptomycin (Basit et al., 2014). In addition, higher mortality among MDR-TB patient is associated with the used of anti-retroviral therapy (ART) before initiation of MDR-TB treatment (Umanah, Ncayiyana, Padanilam, & Nyasulu, 2015), and CD4 count ≤100 cells/mm3 (J. C. M. Brust et al., 2018). Therefore, it is important to address the determining factors to understand adverse and successful treatment outcomes.

2.3 Hepatitis C

The first antibody test to HCV became available in 1989 when it was discovered that non-A non-B hepatitis was predominantly caused by HCV (H. J. Alter et al., 1989). The World Health Organization has defined HCV as a bloodborne virus, commonly transmitted through sharing injection materials, reuse and inadequate sterilization of medical equipment, and transfusion of unscreened blood (World Health Organization, 2017d). Although the transmission of HCV was recognized primarily as blood contact, there are other route of transmission such as sexual transmission (Dienstag, 1997), transmission from mother to infant (Ohto et al., 1994), use

of folk remedies such as acupuncture and vacuuming (Kiyosawa et al., 1994), and tattoo and body piercing (Tohme & Holmberg, 2012). The estimated global prevalence of HCV infection was 2.2% (Global Burden Of Hepatitis, 2004), however due to the lack of data from many countries, WHO estimated 71 million people have chronic hepatitis C infection, accounting for 1.34 million deaths in 2015 (World Health Organization, 2017b).

Acute HCV infection is usually mild and the transition of acute to chronic hepatitis C is sub-clinical. Acute HCV infection can be resolved but most frequently progresses to chronic hepatitis (Grebely et al., 2014; Yeung, To, King, & Roberts, 2007). Chronic HCV infection is a slowly progressing disease with persistent liver inflammation leading to cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). Globally, chronic HCV contributed to 27% of hepatic cirrhosis and 25% of HCC (Perz, Armstrong, Farrington, Hutin, & Bell, 2006). However, with the development of direct-acting antiviral (DAA), HCV treatment is more available and providing the promising results (Cotte et al., 2016; Sulkowski et al., 2014). Despite these advancement, the epidemiological studies on HCV and its interaction on different diseases especially patients with HIV and TB are still needed to explore.

2.4 Tuberculosis/ Multidrug-Resistant Tuberculosis and Hepatitis C in HIV population

Approximately 30% of HIV patients are co-infected with Hepatitis C virus (M. J. Alter, 2006; Platt et al., 2016) due to shared routes of transmission. With the improvement in HIV treatment and increase survival of HIV patient, it has emerged as that the liver complication by HCV infection is being a threat to survival of HIV patients. Studies found that HIV infection accelerate the liver disease progression in patients co-infected with HCV (Hernandez & Sherman, 2011). Tuberculosis is more prevalent in HIV population due to weaken immune

system of the host. The pool prevalence of TB/HIV co-infection was 23.51% (95% CI 20.91 –
26.11) with highest among African countries with 31.25% and lowest in United States with
14.84% (Gao, Zheng, & Fu, 2013). Medicines used to treat TB have hepatotoxic potential (Yew
& Leung, 2006). Studies have frequently reported drug-induced hepatotoxicity during TB
treatment among individuals with HCV co-infection (Kwon et al., 2007; Lomtadze et al., 2013).

## 2.5 Summary

The literature review of previous studies highlights –

- MDR-TB treatment requires the use of second-line drugs for long periods of time, and
  side effects of its treatment are common and serious.

- Adverse TB treatment outcomes are common among patients with MDR-TB.

- Knowledge about the impact of HCV infection on MDR TB treatment is lacking,
  especially among patients with HIV.

LITERATURE REFERENCE

Ahmad, N., Javaid, A., Basit, A., Afridi, A. K., Khan, M. A., Ahmad, I., . . . Khan, A. H. (2015). Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. *Int J Tuberc Lung Dis, 19*(9), 1109-1114, i-ii. doi:10.5588/ijtld.15.0167

Alter, H. J., Purcell, R. H., Shih, J. W., Melpolder, J. C., Houghton, M., Choo, Q. L., & Kuo, G. (1989). Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N Engl J Med, 321*(22), 1494-1500. doi:10.1056/NEJM198911303212202

Alter, M. J. (2006). Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol, 44*(1 Suppl), S6-9. doi:10.1016/j.jhep.2005.11.004

Anderson, L. F., Tamne, S., Watson, J. P., Cohen, T., Mitnick, C., Brown, T., . . . Abubakar, I. (2013). Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. *Euro Surveill, 18*(40).

Basit, A., Ahmad, N., Khan, A. H., Javaid, A., Syed Sulaiman, S. A., Afridi, A. K., . . . Ahmad, I. (2014). Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. *PLoS One, 9*(4), e93206. doi:10.1371/journal.pone.0093206

Bastard, M., Sanchez-Padilla, E., Hewison, C., Hayrapetyan, A., Khurkhumal, S., Varaine, F., & Bonnet, M. (2015). Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. *J Infect Dis, 211*(10), 1607-1615. doi:10.1093/infdis/jiu551

Bastos, M. L., Cosme, L. B., Fregona, G., do Prado, T. N., Bertolde, A. I., Zandonade, E., . . . Maciel, E. L. N. (2017). Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. *BMC Infect Dis, 17*(1), 718. doi:10.1186/s12879-017-2810-1

Brust, J. C., Shah, N. S., van der Merwe, T. L., Bamber, S., Ning, Y., Heo, M., . . . Gandhi, N. R. (2013). Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. *J Acquir Immune Defic Syndr, 62*(4), 436-440. doi:10.1097/QAI.0b013e31828175ed

Brust, J. C. M., Shah, N. S., Mlisana, K., Moodley, P., Allana, S., Campbell, A., . . . Gandhi, N. R. (2018). Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa. *Clinical Infectious Diseases, 66*(8), 1246-1253. doi:10.1093/cid/cix1125

Chung-Delgado, K., Guillen-Bravo, S., Revilla-Montag, A., & Bernabe-Ortiz, A. (2015). Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. *PLoS One, 10*(3), e0119332. doi:10.1371/journal.pone.0119332

Cotte, L., Pugliese, P., Valantin, M. A., Cuzin, L., Billaud, E., Duvivier, C., . . . Dat, A. s. G. (2016). Hepatitis C treatment initiation in HIV-HCV coinfected patients. *BMC Infect Dis, 16*, 345. doi:10.1186/s12879-016-1681-1

Dienstag, J. L. (1997). Sexual and perinatal transmission of hepatitis C. *Hepatology, 26*(3 Suppl 1), 66S-70S. doi:10.1002/hep.510260712

Falzon, D., Jaramillo, E., Wares, F., Zignol, M., Floyd, K., & Raviglione, M. C. (2013). Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. *Lancet Infect Dis, 13*(8), 690-697. doi:10.1016/S1473-3099(13)70130-0

Falzon, D., Mirzayev, F., Wares, F., Baena, I. G., Zignol, M., Linh, N., . . . Raviglione, M. (2015). Multidrug-resistant tuberculosis around the world: what progress has been made? *Eur Respir J, 45*(1), 150-160. doi:10.1183/09031936.00101814

Farley, J. E., Ram, M., Pan, W., Waldman, S., Cassell, G. H., Chaisson, R. E., . . . Van der Walt, M. (2011). Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. *PLoS One, 6*(7), e20436. doi:10.1371/journal.pone.0020436

Gandhi, N. R., Andrews, J. R., Brust, J. C., Montreuil, R., Weissman, D., Heo, M., . . . Shah, N. S. (2012). Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. *Int J Tuberc Lung Dis, 16*(1), 90-97. doi:10.5588/ijtld.11.0153

Gao, J., Zheng, P., & Fu, H. (2013). Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One, 8(5), e64915. doi:10.1371/journal.pone.0064915

Gillespie, S. H. (2002). Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. *Antimicrob Agents Chemother, 46*(2), 267-274.

Global Burden Of Hepatitis, C. W. G. (2004). Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol, 44*(1), 20-29. doi:10.1177/0091270003258669

Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M. S., Rice, T. M., Bruneau, J., . . . In, C. S. G. (2014). The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology, 59*(1), 109-120. doi:10.1002/hep.26639

Hernandez, M. D., & Sherman, K. E. (2011). HIV/hepatitis C coinfection natural history and disease progression. *Curr Opin HIV AIDS, 6*(6), 478-482. doi:10.1097/COH.0b013e32834bd365

Isaakidis, P., Casas, E. C., Das, M., Tseretopoulou, X., Ntzani, E. E., & Ford, N. (2015). Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. *Int J Tuberc Lung Dis, 19*(8), 969-978. doi:10.5588/ijtld.15.0123

Jain, K., Desai, M., Solanki, R., & Dikshit, R. K. (2014). Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. *J Pharmacol Pharmacother, 5*(2), 145-149. doi:10.4103/0976-500X.130062

Kang, Y. A., Choi, Y. J., Cho, Y. J., Lee, S. M., Yoo, C. G., Kim, Y. W., . . . Yim, J. J. (2006). Cost of treatment for multidrug-resistant tuberculosis in South Korea. *Respirology, 11*(6), 793-798. doi:10.1111/j.1440-1843.2006.00948.x

Kibret, K. T., Moges, Y., Memiah, P., & Biadgilign, S. (2017). Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. *Infect Dis Poverty, 6*(1), 7. doi:10.1186/s40249-016-0214-x

Kikvidze, M., & Ikiashvili, L. (2014). Comorbidities and MDR-TB treatment outcomes in Georgia-2009-11 cohort. *European Respiratory Journal, 44*.

Kiyosawa, K., Tanaka, E., Sodeyama, T., Yoshizawa, K., Yabu, K., Furuta, K., . . . et al. (1994). Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. *Gastroenterology, 106*(6), 1596-1602.

Kwon, Y. S., Koh, W. J., Suh, G. Y., Chung, M. P., Kim, H., & Kwon, O. J. (2007). Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. *Chest, 131*(3), 803-808. doi:10.1378/chest.06-2042

Lee, S. S., Lee, C. M., Kim, T. H., Kim, J. J., Lee, J. M., Kim, H. J., . . . Kim, D. Y. (2016). Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis, 20*(6), 800-805. doi:10.5588/ijtld.15.0668

Lomtadze, N., Kupreishvili, L., Salakaia, A., Vashakidze, S., Sharvadze, L., Kempker, R. R., . . . Blumberg, H. M. (2013). Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. *PLoS One, 8*(12), e83892. doi:10.1371/journal.pone.0083892

Marks, S. M., Flood, J., Seaworth, B., Hirsch-Moverman, Y., Armstrong, L., Mase, S., . . . Consortium, T. B. E. S. (2014). Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. *Emerg Infect Dis, 20*(5), 812-821. doi:10.3201/eid2005.131037

Micheletti, V. C., Kritski, A. L., & Braga, J. U. (2016). Clinical Features and Treatment Outcomes of Patients with Drug-Resistant and Drug-Sensitive Tuberculosis: A Historical Cohort Study in Porto Alegre, Brazil. *PLoS One, 11*(8), e0160109. doi:10.1371/journal.pone.0160109

Nakai, K., Win, K. M., Oo, S. S., Arakawa, Y., & Abe, K. (2001). Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C/hepatitis G virus in Myanmar. *J Clin Microbiol, 39*(4), 1536-1539. doi:10.1128/JCM.39.4.1536-1539.2001

Ohto, H., Terazawa, S., Sasaki, N., Sasaki, N., Hino, K., Ishiwata, C., . . . et al. (1994). Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of

Hepatitis C Virus Collaborative Study Group. *N Engl J Med, 330*(11), 744-750. doi:10.1056/NEJM199403173301103

Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol, 45*(4), 529-538. doi:10.1016/j.jhep.2006.05.013

Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., . . . Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis, 16*(7), 797-808. doi:10.1016/S1473-3099(15)00485-5

Podewils, L. J., Gler, M. T., Quelapio, M. I., & Chen, M. P. (2013). Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. *PLoS One, 8*(7), e70064. doi:10.1371/journal.pone.0070064

Ramachandran, G., & Swaminathan, S. (2015). Safety and tolerability profile of second-line anti-tuberculosis medications. *Drug Saf, 38*(3), 253-269. doi:10.1007/s40264-015-0267-y

Schnippel, K., Rosen, S., Shearer, K., Martinson, N., Long, L., Sanne, I., & Variava, E. (2013). Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. *Trop Med Int Health, 18*(1), 109-116. doi:10.1111/tmi.12018

Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., . . . Group, A. I. S. (2014). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med, 370*(3), 211-221. doi:10.1056/NEJMoa1306218

Tohme, R. A., & Holmberg, S. D. (2012). Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. *Clinical Infectious Diseases, 54*(8), 1167-1178. doi:10.1093/cid/cir991

Torun, T., Gungor, G., Ozmen, I., Bolukbasi, Y., Maden, E., Bicakci, B., . . . Tahaoglu, K. (2005). Side effects associated with the treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis, 9*(12), 1373-1377.

Umanah, T., Ncayiyana, J., Padanilam, X., & Nyasulu, P. S. (2015). Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa. *BMC Infect Dis, 15*, 478. doi:10.1186/s12879-015-1214-3

World Health Organization. (2013). WHO definitions and reporting framework for tuberculosis. *18*(16), 20455.

World Health Organization. (2014). The End TB Strategy.

World Health Organization. (2015). Use of high burden country lists for TB by WHO in the post-2015 era.

World Health Organization. (2016). WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. In. Geneva.

World Health Organization. (2017a). Country profiles FOR 30 HIGH TB BURDEN COUNTRIES.

World Health Organization. (2017b). Global Hepatitis Report 2017.

World Health Organization. (2017c). *Global tuberculosis report 2017*. Retrieved from Geneva: http://www.who.int/tb/publications/global_report/en/

World Health Organization. (2017d). Hepatitis C Key Facts.

Xu, C., Pang, Y., Li, R., Ruan, Y., Wang, L., Chen, M., & Zhang, H. (2018). Clinical outcome of
multidrug-resistant tuberculosis patients receiving standardized second-line treatment
regimen in China. *J Infect, 76*(4), 348-353. doi:10.1016/j.jinf.2017.12.017

Yang, T. W., Park, H. O., Jang, H. N., Yang, J. H., Kim, S. H., Moon, S. H., . . . Kang, D. H.
(2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a
tuberculosis referral hospital in South Korea: A retrospective study. *Medicine
(Baltimore), 96*(28), e7482. doi:10.1097/MD.0000000000007482

Yeung, L. T., To, T., King, S. M., & Roberts, E. A. (2007). Spontaneous clearance of childhood
hepatitis C virus infection. *J Viral Hepat, 14*(11), 797-805. doi:10.1111/j.1365-
2893.2007.00873.x

Yew, W. W., & Leung, C. C. (2006). Antituberculosis drugs and hepatotoxicity. *Respirology,
11*(6), 699-707. doi:10.1111/j.1440-1843.2006.00941.x

Zhang, Y., Wu, S., Xia, Y., Wang, N., Zhou, L., Wang, J., . . . Zhan, S. (2017). Adverse Events
Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An
Ambispective Cohort Study. *Med Sci Monit, 23*, 2348-2356.

# CHAPTER III

## MANUSCRIPT

### Introduction

Tuberculosis (TB) is one of the top 10 causes of death worldwide. Multidrug-resistant tuberculosis (MDR-TB), a form of TB that is resistant to two of the most effective first-line anti-TB drugs – rifampicin and isoniazid, is a global public health crisis. In 2016, the worldwide prevalence of MDR-TB was 4% among new TB cases and 19% among retreatment cases [1]. Compared to drug susceptible TB, treatment of MDR-TB is substantially longer (i.e. 9 to 24 months) [2], requires more expensive and toxic drugs and has a high mortality rate [3, 4]. In addition, hepatitis co-infection is a common comorbidity in patients with TB [5], potentially increasing the risk of hepatoxicity and mortality during TB treatment [6-8]. For example, hepatitis C virus (HCV) causes acute and chronic liver conditions and is associated with adverse TB treatment outcomes [9-11]. Given the increased risk of MDR-TB treatment on hepatotoxicity [12], HCV co-infection may augment the risk of liver disease during TB treatment leading to even greater risk of adverse MDR-TB treatment outcome.

MDR-TB treatment success rates vary by region, but the median treatment success rate is only 53% (IQR 40 – 70%) in high TB burden countries [13-15]. Many patient factors contribute to adverse MDR-TB treatment outcomes, but HIV co-infection is of particular concern given its link to TB incidence [16] and high mortality during TB treatment [17, 18]. With a potential link between HCV and HIV among patients with drug-resistant TB [19], it is important to understand the impact of HCV on MDR-TB treatment outcomes in the context of patients with HIV.

Further epidemiologic data on the role of HCV on adverse MDR-TB outcomes are needed to improve treatment guidelines for patients receiving second line anti-TB medicines

with multiple risk factors for hepatotoxicity. Improved knowledge regarding the role of HCV on adverse MDR-TB treatment outcome in patients with HIV may inform future clinical HIV-TB guidelines including side effects monitoring and risk stratification for patients. Mortality due to MDR-TB is high even with the proper treatment [3, 4]. Therefore, even incremental improvements in MDR-TB treatment outcomes may substantially improve clinical care for high HIV/TB burden countries like Myanmar. In this context, we aimed to analyze the association between HCV infection and adverse MDR-TB outcome among patients with MDR-TB and HIV.

## Methods

### *Study design*

We performed a retrospective cohort study using previously collected data from the Médecins Sans Frontières (MSF – Doctors without Borders) HIV clinic in Myanmar during 2009-2017. Participants were registered at the time of TB diagnosis and followed during standard MDR-TB and HIV treatment.

### *Setting and participants*

In Myanmar, MDR-TB treatment became available in 2009 with a National Tuberculosis Program (NTP) and MSF initiated a pilot treatment project in Yangon. Following the pilot, a Programmatic Management of Drug-resistant Tuberculosis (PMDT) program was extended in 2012 to accelerate the MDR-TB treatment program throughout Myanmar.

Eligible patients for the study included all adults aged ≥18 years receiving HIV treatment at MSF Myanmar who had MDR-TB diagnosed by Xpert MTB/RIF test and were confirmed by sputum culture and conventional drug sensitivity test (DST).  Solid or liquid sputum culture (Lowenstein-Jensen media or Mycobacterium Growth Indicator Tube) were used to confirm

Xpert MTB/RIF results and drug resistance patterns.  Patients without a final TB treatment outcome or unknown HCV status were excluded.

*Measures and definitions*

The primary outcome of the study was MDR-TB treatment outcome which was defined according to WHO categories of cured, treatment completed, treatment failed, died, lost to follow-up, and not evaluated [20]. We defined the primary outcome dichotomously as adverse (default, failed, died, not evaluated) or favorable (cured, completed).

The study's primary exposure was HCV status, classified as positive or negative based on OraQuick® hepatitis C antibody test, a point-of-care test used to detect HCV infection. After Hepatitis C treatment guideline had implemented in 2015, all HIV patients were routinely tested with OraQuick® at the clinic laboratory by laboratory technicians.

Other covariates of interest included demographic and socioeconomic characteristics which were assessed during the clinical consultation. Clinical symptoms of TB, and HIV were examined by physicians during clinic visits. Routine laboratory tests such as CD4 count, complete blood count, and other tests for MDR-TB side effects such as liver function tests were performed in MSF reference laboratories and recorded in the database accordingly.

*Statistical methods*

We used chi-square and Fisher's exact tests to examine the bivariate association between categorical variables and 1) HCV status and 2) adverse MDR-TB outcome. The association between both HCV and MDR-TB outcome with continuous variables such as age, BMI, CD4 count, and laboratory tests were assessed using Wilcoxon rank sum test. Multivariable logistic regression models were used to estimate the adjusted association between HCV and MDR-TB

treatment outcome. A two-sided p-value <0.05 was considered statistically significant in all analyses. SAS 9.4 (Cary, NC) was used to perform all analyses.

## *Ethical approval*

Georgia State University and MSF Institutional Review Boards reviewed and approved the study's protocol.

## Results

### *Participant characteristics*

During the study period, a total of 454 patients registered in the MDR-TB treatment program and 387 patients (85%) initiated MDR-TB treatment with second-line drugs. Of these, 308 (68%) patients had MDR-TB final treatment outcome recorded and 220 with known HCV status were included in the analysis (Figure 4.1). Among the 220 patients in our analyses, 8% (N=17) were HCV positive, among them the median age was 35 years (IQR 30 – 40) and the majority (67%, N=148) were male.

### *Clinical and laboratory characteristics associated with HCV among MDR-TB patients with HIV (Table 3.1)*

Out of 220 patients with HCV test results, the majority of patients had pulmonary TB – 93% (N=185) in HCV negative group and all 100% (N=17) in HCV positive group (P=0.61). Also, most of the cases were retreatment cases: 63% (N=125) among HCV negative and (71% (N=12) among HCV positive were previously treated for TB (P=0.52). Regarding HIV clinical stage to define the severity of HIV infection, 63% (N=121) were in stage 3 and 37% (N=72) were in stage 4 among HCV negative patients, while 59% (N=10) were stage 3 and 41% (N=7)

stage 4 in HCV positive group (P=0.75). Almost all patients received HIV treatment – 95% (N=193) of HCV negative and 94% (N=16) HCV positive were on treatment for HIV (P=0.60). Cotrimoxazole preventive therapy (CPT) prior to MDR-TB treatment initiation was more common among HCV negative patients (87%) compared to HCV positive patients (62%) (P=0.02). Regarding TB laboratory results, 58% (N=117) of HCV negative patients were sputum AFB smear-positive, and 76% (N=13) among HCV positive patients were smear-positive (P=0.13). CD4 counts were non-significantly higher in HCV positive patients (median 261 cells/μL; IQR 148 – 414) compared to HCV negative patients (median 144 cells/μL; IQR 63 – 274) (P=0.06). Alanine aminotransferase (ALT) levels were not significantly different comparing HCV positive patients (median 26.5 IU/L; IQR 22.1 – 31.3) and HCV negative patients (median 25.6 IU/L; IQR18.1 – 40.85) (P=0.97).

*Factors associated with adverse MDR-TB treatment outcome (Table 3.2)*

Among study participants 35% (N=77) had an adverse outcome while 65% (N=143) had a favorable treatment outcome. Among patients with pulmonary TB, 34% (68/202) had an adverse treatment outcome, and in patients with extrapulmonary, 46% (6/13) had an adverse outcome (P=0.38). Regarding previous TB treatment history, 43% (34/79) of new cases and 30% (42/137) of retreatment cases had adverse treatment outcomes (P=0.07). HIV clinical stage and anti-retroviral therapy provided a difference in MDR-TB treatment outcome. Nearly one-third (32%) of patients receiving HIV treatment had adverse outcomes, while the majority (91%) of those without HIV treatment had adverse MDR-TB treatment outcomes (P=<0.01). The proportion of patients with cotrimoxazole prophylaxis at enrollment who had adverse outcome was non-significantly greater 36% (63/177) compared to those without prophylaxis 29% (9/31)

(P=0.48). Regarding TB laboratory results, 32% (41/130) of patients who were sputum smear positive had adverse outcome compared to 40% (36/90) with smear negative or non-conclusive had an adverse outcome (P=0.20). The median CD4 count was different by treatment outcome: among those with adverse outcomes the median CD4 count was 138.5 cells/µL (IQR 64 – 256) compared to 173.5 cells/µL (IQR 83 – 365) among those with favorable treatment outcomes (P=0.41).

*Association between HCV and adverse MDR-TB outcome (Table 3.3)*

In an unadjusted model, the odds of adverse treatment outcome among patients with HCV infection was 1.33 (95% CI 0.49 – 3.65) times the odds of those without HCV (Table 3). In a model adjusted for age and gender, the odds ratio of adverse treatment outcome comparing those with HCV to those without was 1.31 (95% CI 0.47 – 3.61). Additional models adjusted for age, gender, and illicit drug use (aOR 1.28 95% CI 0.25 – 6.50) and for previous TB treatment history, age, and gender (aOR 1.43 95% CI 0.50 – 4.03) did not substantially change the estimated association between HCV and adverse MDR-TB treatment outcome.

**Discussion**

This study assessed the relationship between HCV and adverse MDR-TB treatment outcomes among patients with HIV co-infection in Myanmar. We observed a high proportion of adverse MDR-TB outcomes among patients with HIV—overall more than one-third of patients failed, died, or were lost to follow up during second-line TB treatment. We did not detect a significant difference in the proportion of patients with and without HCV who had adverse outcomes.

30

The treatment outcome for MDR-TB tuberculosis varies widely among high TB burden countries, with a median treatment success rate of 53% and IQR 40 – 70% [13] which is greatly lower than the goal of 75% posed by the WHO Global Plan to End TB [21]. In our study, the overall treatment success rate was 65%, with 55% cured and 10% completed. Unexpectedly, in our patient population, the proportion achieving treatment success among HCV negative patients was similar to those with HCV infection. However, the HCV positive group had a slightly lower success rate with a considerable proportion (29%) of patients with the outcome not evaluated.

Although not the objective of our study, we found that HIV treatment at the time of registration into the MDR-TB program predicted treatment success. Unlike our findings, previous studies of MDR-TB patients with HIV have reported higher mortality among those using ART at the time of TB treatment [22], likely due to immune reconstitution inflammatory syndrome (IRIS). The majority (62%) of patients with MDR-TB in our study were retreatment cases, therefore IRIS was more likely to have occurred during the initial TB disease treatment.

This study was subject to a number of limitations. First, the study population only included half of all registered MDR-TB patients because of incomplete testing for HCV antibodies and therefore the study sample size was underpowered to test our hypothesis. Moreover, standard testing for HCV began in 2015 after the MDR-TB program had been on-going. Consequently, a large proportion of patients in our study only had HCV test results performed after the initiation of MDR-TB treatment. However, because HCV and HIV may have similar modes of transmission [23, 24], it is likely a large proportion of patients were co-infected with HCV and HIV at the time of MDR-TB treatment. Third, the quality of data is another limitation of the study. Patients' history, clinical symptoms and medical examination were collected by physicians but there were no quality control mechanisms in place to ensure data

31

www.manaraa.com

The treatment outcome for MDR-TB tuberculosis varies widely among high TB burden countries, with a median treatment success rate of 53% and IQR 40 – 70% [13] which is greatly lower than the goal of 75% posed by the WHO Global Plan to End TB [21]. In our study, the overall treatment success rate was 65%, with 55% cured and 10% completed. Unexpectedly, in our patient population, the proportion achieving treatment success among HCV negative patients was similar to those with HCV infection. However, the HCV positive group had a slightly lower success rate with a considerable proportion (29%) of patients with the outcome not evaluated.

Although not the objective of our study, we found that HIV treatment at the time of registration into the MDR-TB program predicted treatment success. Unlike our findings, previous studies of MDR-TB patients with HIV have reported higher mortality among those using ART at the time of TB treatment [22], likely due to immune reconstitution inflammatory syndrome (IRIS). The majority (62%) of patients with MDR-TB in our study were retreatment cases, therefore IRIS was more likely to have occurred during the initial TB disease treatment.

This study was subject to a number of limitations. First, the study population only included half of all registered MDR-TB patients because of incomplete testing for HCV antibodies and therefore the study sample size was underpowered to test our hypothesis. Moreover, standard testing for HCV began in 2015 after the MDR-TB program had been on-going. Consequently, a large proportion of patients in our study only had HCV test results performed after the initiation of MDR-TB treatment. However, because HCV and HIV may have similar modes of transmission [23, 24], it is likely a large proportion of patients were co-infected with HCV and HIV at the time of MDR-TB treatment. Third, the quality of data is another limitation of the study. Patients' history, clinical symptoms and medical examination were collected by physicians but there were no quality control mechanisms in place to ensure data

were complete. Fourth, most of the patient risk factors were self-reported, and therefore several behavioral predictors of poor MDR-TB outcome (i.e., smoking, alcohol use, and illicit drug use [25-28]) were likely under reported. Liver function tests such as serum bilirubin, alanine amino transferase (ALT), aspartate amino transferase (AST) are standard of care [29] in MSF Myanmar. However, missing data prohibited the classification of hepatotoxicity in our patients. Last, we were unable to differentiate between acute and chronic HCV infection as the point-of-care test used to measure HCV did not provide HCV RNA confirmation.

Despite limitations, this is the first study resulting from a pilot MDR-TB treatment project at MSF and serves to describe the initial treatment outcomes of MDR-TB patients co-infected with HIV and HCV in Myanmar. Importantly, as our study used data from the first MDR-TB treatment program from Myanmar at the time, patients from several regions were included. Therefore, we believe the results of the study are widely generalizable to patients with MDR-TB and HIV in the country of Myanmar.

**Conclusion**

There is a growing concern that poor MDR-TB treatment outcomes will greatly inhibit the EndTB strategy. Our initial findings from Myanmar point to a high rate of MDR-TB treatment failure in patients with HIV and suggest that additional work is needed to understand the relationship between HCV, hepatotoxicity, and poor TB outcomes among patients with MDR-TB and HIV.

## References

1.      World Health Organization, *Global tuberculosis report 2017*. 2017: Geneva.

2.      World Health Organization, *WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update*. 2016: Geneva.

3.      Chung-Delgado, K., et al., *Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.* PLoS One, 2015. **10**(3): p. e0119332.

4.      Gandhi, N.R., et al., *Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.* Int J Tuberc Lung Dis, 2012. **16**(1): p. 90-7.

5.      Oprea, C., et al., *Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users.* J Int AIDS Soc, 2014. **17**(4 Suppl 3): p. 19625.

6.      Chang, T.E., et al., *The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis.* J Chin Med Assoc, 2018. **81**(2): p. 111-118.

7.      Kwon, Y.S., et al., *Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.* Chest, 2007. **131**(3): p. 803-808.

8.      Chien, J.Y., et al., *Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment.* Int J Tuberc Lung Dis, 2010. **14**(5): p. 616-21.

9.      World Health Organization, *Hepatitis C Key Facts.* 2017.

10.     Lomtadze, N., et al., *Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis.* PLoS One, 2013. **8**(12): p. e83892.

11.     Lee, S.S., et al., *Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis.* Int J Tuberc Lung Dis, 2016. **20**(6): p. 800-5.

12. Ramappa, V. and G.P. Aithal, *Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.* J Clin Exp Hepatol, 2013. **3**(1): p. 37-49.

13. Falzon, D., et al., *Multidrug-resistant tuberculosis around the world: what progress has been made?* Eur Respir J, 2015. **45**(1): p. 150-60.

14. Kibret, K.T., et al., *Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.* Infect Dis Poverty, 2017. **6**(1): p. 7.

15. Mpagama, S.G., et al., *Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.* PLoS One, 2013. **8**(5): p. e62034.

16. Farley, J.E., et al., *Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.* PLoS One, 2011. **6**(7): p. e20436.

17. van der Walt, M., J. Lancaster, and K. Shean, *Tuberculosis Case Fatality and Other Causes of Death among Multidrug-Resistant Tuberculosis Patients in a High HIV Prevalence Setting, 2000-2008, South Africa.* Plos One, 2016. **11**(3).

18. Shenoi, S., et al., *Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.* Current Opinion in Infectious Diseases, 2009. **22**(1): p. 11-17.

19. Suchindran, S., E.S. Brouwer, and A. Van Rie, *Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review.* Plos One, 2009. **4**(5).

20. World Health Organization, *WHO definitions and reporting framework for tuberculosis.*00202013. **18**(16): p. 20455.

21. World Health Organization, S., *Global Plan to Stop TB 2011-2015.*

22.    Umanah, T., et al., *Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.* BMC Infect Dis, 2015. **15**: p. 478.

23.    Tibbs, C.J., *Methods of transmission of hepatitis C.* J Viral Hepat, 1995. **2**(3): p. 113-9.

24.    Jin, F., G.V. Matthews, and A.E. Grulich, *Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.* Sex Health, 2017. **14**(1): p. 28-41.

25.    Fregona, G., et al., *Risk factors associated with multidrug-resistant tuberculosis in Espirito Santo, Brazil.* Rev Saude Publica, 2017. **51**(0): p. 41.

26.    Magee, M.J., et al., *Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia.* PLoS One, 2014. **9**(4): p. e94890.

27.    Duraisamy, K., et al., *Does Alcohol Consumption during Multidrug-resistant Tuberculosis Treatment Affect Outcome?: A Population-based Study in Kerala, India.* Ann Am Thorac Soc, 2014. **11**(5): p. 712-8.

28.    Deiss, R.G., T.C. Rodwell, and R.S. Garfein, *Tuberculosis and Illicit Drug Use: Review and Update.* Clinical Infectious Diseases, 2009. **48**(1): p. 72-82.

29.    Giannini, E.G., R. Testa, and V. Savarino, *Liver enzyme alteration: a guide for clinicians.* CMAJ, 2005. **172**(3): p. 367-79.

Table 3.1: Demographic, clinical, and laboratory characteristics of patients with MDR-TB by Hepatitis C infection status

| Participant Characteristics | Hepatitis C Negative N= 203 (92%) | Hepatitis C Positive N= 17 (8%) | Total N= 220 | P * Value |
|---|---|---|---|---|
| **Demographic characteristics** | | | | |
| Age | | | | |
| Median (IQR) | 35 (30 – 40) | 36 (32 – 41) | 35 (30 – 40) | 0.35 [a] |
| Gender | | | | |
| Female | 69 (34) | 3 (18) | 72 (33) | 0.17 |
| Male | 134 (66) | 14 (82) | 148 (67) | |
| Marital status | | | | |
| Not Disclosed | 17 (8) | 1 (6) | 18 (8) | 0.23 [b] |
| Married | 102 (50) | 7 (41) | 109 (50) | |
| Single | 46 (23) | 5 (29) | 51 (23) | |
| Divorced | 10 (5) | 2 (12) | 12 (5) | |
| Widowed | 20 (10) | 0 | 20 (9) | |
| Separated | 8 (4) | 2 (12) | 10 (5) | |
| Employment | | | | |
| Not Disclosed | 44 (22) | 1 (6) | 45 (20) | 0.15 [b] |
| Employed | 50 (25) | 4 (24) | 54 (24) | |
| Pensioner | 0 | 0 | 0 | |
| Student | 0 | 0 | 0 | |
| Unemployed | 86 (42) | 8 (47) | 94 (43) | |
| Housework | 8 (4) | 0 | 8 (4) | |
| Others | 15 (7) | 4 (24) | 19 (9) | |
| Risk Factors | | | | |
| Prison | | | | |
| Not been in Prison | 195 (96) | 16 (94) | 211 (96) | 0.70 |
| Ever been in Prison | 8 (4) | 1 (6) | 9 (4) | |
| Alcohol use | | | | |
| No | 190 (96) | 16 (94) | 206 (94) | 0.53 [b] |
| Yes | 8 (4) | 1 (6) | 9 (4) | |
| Missing | 5 | 0 | 5 (2) | |
| Illicit Drug use | | | | |
| No | 81 (40) | 7 (41) | 88 (40) | **< 0.01** [b c] |
| Yes | 0 | 2 (12) | 2 (1) | |
| Missing | 122 (60) | 8 (47) | 130 (59) | |
| Tobacco use | | | | |
| No | 190 (94) | 15 (88) | 205 (93) | 0.33 [b] |
| Yes | 13 (6) | 2 (12) | 15 (7) | |

| Participant Characteristics | Hepatitis C Negative N= 203 (92%) | Hepatitis C Positive N= 17 (8%) | Total N= 220 | P * Value |
|---|---|---|---|---|
| Homeless | | | | |
| No | 201 (99) | 17 | 218 (99) | 1.00 [b] |
| Yes | 2 (1) | 0 | 2 (1) | |
| | | | | |
| Migrant | | | | |
| No | 202 (99) | 17 | 219 (99) | 1.00 [b] |
| Yes | 1 (1) | 0 | 1 (1) | |
| | | | | |
| Prostitution | | | | |
| No | 200 (99) | 17 | 217 (99) | 1.00 [b] |
| Yes | 3 (1) | 0 | 3 (1) | |
| **Clinical characteristics** | | | | |
| Site of TB | | | | |
| Pulmonary | 185 (93) | 17 | 202 (92) | 0.61 [b] |
| Extra-pulmonary | 13 (7) | 0 | 13 (6) | |
| Missing | 5 | | 5 (2) | |
| TB treatment history | | | | |
| New Case | 74 (37) | 5 (29) | 79 (36) | 0.75 [b] |
| Failure | 47 (23) | 6 (35) | 53 (24) | |
| Relapse | 71 (35) | 6 (35) | 77 (35) | |
| Treatment | 5 (2) | 0 | 5 (2) | |
| interrupted | 2 (1) | 0 | 2 (1) | |
| Unknown | 4 (2) | | 4 (2) | |
| Previous TB history | | | | |
| New Case | 74 (36) | 5 (29) | 79 (36) | 0.52 |
| Retreatment Case | 125 (62) | 12 (71) | 137 (62) | |
| Missing | 4 (2) | 0 | 4 (2) | |
| HIV clinical stage | | | | |
| Stage 3 | 121 (63) | 10 (59) | 131 (60) | 0.75 |
| Stage 4 | 72 (37) | 7 (41) | 79 (39) | |
| Missing | 10 | 0 | 10 (5) | |
| HIV treatment | | | | |
| No | 10 (5) | 1 (6) | 11 (5) | 0.60 [b] |
| Yes | 193 (95) | 16 (94) | 209 (95) | |
| Cotrimoxazole prophylaxis at enrollment | | | | |
| No | 25 (12) | 6 (38) | 31 (14) | **0.02** [b] |
| Yes | 167 (82) | 10 (62) | 177 (80) | |
| Missing | 11 (6) | 1 | 12 (6) | |

| Participant Characteristics | Hepatitis C Negative N= 203 (92%) | Hepatitis C Positive N= 17 (8%) | Total N= 220 | P * Value |
|---|---|---|---|---|
| BMI | | | | |
| Median (IQR) (N = 186) | 17.1 (15.5 – 18.6) | 16.65 (14.05 – 18) | 17.05 (15.4 – 18.6) | 0.24 [a] |
| Clinical Symptoms | | | | |
| Fever | | | | |
| No | 113 (56) | 12 (71) | 125 (57) | 0.23 |
| Yes | 90 (44) | 5 (29) | 95 (43) | |
| Sweat | | | | |
| No | 162 (80) | 16 (94) | 178 (81) | 0.21 [b] |
| Yes | 41 (20) | 1 (6) | 42 (19) | |
| Dry cough | | | | |
| No | 180 (89) | 15 (88) | 195 (87) | 1.00 [b] |
| Yes | 23 (11) | 2 (12) | 25 (13) | |
| Productive cough | | | | |
| No | 121 (60) | 9 (53) | 130 (59) | 0.59 |
| Yes | 82 (40) | 8 (47) | 90 (41) | |
| Blood spitting | | | | |
| No | 197 (97) | 17 | 214 (97) | 1.00 [b] |
| Yes | 6 (3) | 0 | 6 (3) | |
| Chest Pain | | | | |
| No | 172 (85) | 16 (94) | 188 (85) | 0.48 [b] |
| Yes | 31 (15) | 1 (6) | 32 (15) | |
| Loss of Appetite | | | | |
| No | 126 (62) | 11 (65) | 137 (62) | 0.83 |
| Yes | 77 (38) | 6 (35) | 83 (38) | |
| Weight Loss | | | | |
| No | 126 (62) | 11 (65) | 137 (62) | 0.83 |
| Yes | 77 (38) | 6 (35) | 83 (38) | |
| Dyspnea | | | | |
| No | 149 (73) | 14 (82) | 163 (74) | 0.57 [b] |
| Yes | 54 (27) | 3 (18) | 57 (26) | |

| Participant Characteristics | Hepatitis C Negative N= 203 (92%) | Hepatitis C Positive N= 17 (8%) | Total N= 220 | P * Value |
|---|---|---|---|---|
| **Laboratory characteristics** | | | | |
| Sputum smear result | | | | |
|   Not conclusive | 6 (3) | 0 | 6 (3) | 0.41 |
|   Negative | 68 (36) | 4 (24) | 72 (33) | |
|   Positive | 117 (61) | 13 (76) | 130 (59) | |
|   Missing | 12 | 0 | 12 (5) | |
| Sputum smear result | | | | |
|   Negative & non-conclusive | 86 (42) | 4 (24) | 90 (41) | 0.13 |
|   Positive | 117 (58) | 13 (76) | 130 (59) | |
| CD4 count (cells/μL) | | | | |
|   Median (IQR) (N = 120) | 144 (63 – 274) | 261 (148 – 414) | 161 (73 – 296) | 0.06 [a] |
| ALT (IU/L) | | | | |
|   Median (IQR) (N = 93) | 25.6 (18.1 – 40.85) | 26.5 (22.1 – 31.3) | 26 (18.2 – 40.4) | 0.97 [a] |
| *Primary outcome variable* | | | | |
| MDR-TB Treatment outcome [^] | | | | |
|   Completed | 20 (10) | 1 (6) | 21 (10) | **0.03** [b] |
|   Cured | 113 (55) | 9 (53) | 122 (55) | |
|   Defaulter | 22 (11) | 0 | 22 (10) | |
|   Died | 30 (15) | 1 (6) | 31 (14) | |
|   Failure | 2 (1) | 1 (6) | 3 (1) | |
|   Not evaluated | 16 (8) | 5 (29) | 21 (10) | |
| MDRTB Treatment outcome | | | | |
|   Favorable | 133 (66) | 10 (59) | 143 (65) | 0.58 |
|   Adverse | 70 (34) | 7 (41) | 77 (35) | |

Abbreviation: IQR – interquartile range, BMI – Body Mass Index, ALT – alanine
aminotransferase, MDRTB – Multidrug-resistant Tuberculosis

* chi-square test with 2-sided probability

a Wilcoxon Scores (Rank Sums)

b Fisher's Exact Test

c included the missing values

^ WHO definition framework for TB treatment outcome

Table 3.2: Factors associated with MDR-TB treatment outcome and HCV infection, univariate analysis

| Participant Characteristics | Adverse Treatment outcome N= 77 (35%) | Favorable Treatment Outcome N= 143 (65%) | Total N= 220 | P value * |
|---|---|---|---|---|
| **Primary exposure variable** | | | | |
| Hepatitis C Negative | 70 (34) | 133 (66) | 203 (92) | 0.58 |
| Hepatitis C Positive | 7 (41) | 10 (59) | 17 (8) | |
| **Demographic Characteristics** | | | | |
| Age, years | | | | |
| Median (IQR) | 35 (31 – 41) | 35 (30 – 40) | 35 (30 – 40) | 0.96 [a] |
| Gender | | | | |
| Female | 24 (33) | 48 (67) | 72 (33) | 0.72 |
| Male | 53 (36) | 95 (64) | 148 (67) | |
| Marital status | | | | |
| Not Disclosed | 9 (50) | 9 (50) | 18 (8) | 0.16 |
| Married | 33 (30) | 76 (70) | 109 (50) | |
| Single | 21 (41) | 30 (59) | 51 (23) | |
| Divorced | 3 (25) | 9 (75) | 12 (5) | |
| Widowed | 5 (25) | 15 (75) | 20 (9) | |
| Separated | 6 (60) | 4 (40) | 10 (5) | |
| Employment | | | | |
| Not Disclosed | 18 (40) | 27 (60) | 45 (20) | 0.36 |
| Employed | 22 (41) | 32 (59) | 54 (25) | |
| Pensioner | | | 0 | |
| Student | | | 0 | |
| Unemployed | 26 (28) | 68 (72) | 94 (43) | |
| Housework | 4 (50) | 4 (50) | 8 (4) | |
| Others | 7 (37) | 12 (63) | 19 (9) | |
| Risk Factors | | | | |
| Prison risk factor | | | | |
| Not been in Prison | 75 (36) | 136 (64) | 211 (96) | 0.50 [b] |
| Ever been in Prison | 2 (22) | 7 (78) | 9 (4) | |
| Alcohol use | | | | |
| No | 73 (35) | 133 (65) | 206 (94) | 1.00 [b] |
| Yes | 3 (33) | 6 (67) | 9 (4) | |
| Missing | 1 | 4 | 5 (2) | |
| Illicit Drug use | | | | |
| No | 31 (35) | 57 (65) | 88 (40) | 1.00 [b] |
| Yes | 1 (50) | 1 (50) | 2 (1) | |
| Missing | 45 (35) | 85 (65) | 130 (59) | |

40

| Participant Characteristics | Adverse Treatment outcome N= 77 (35%) | Favorable Treatment Outcome N= 143 (65%) | Total N= 220 | P value * |
|---|---|---|---|---|
| **Tobacco use** | | | | |
| No | 72 (35) | 133 (65) | 205 (93) | 0.89 |
| Yes | 5 (33) | 10 (67) | 15 (7) | |
| | | | | |
| **Homeless** | | | | |
| No | 77 (35) | 141 (65) | 218 (99) | 0.54 [b] |
| Yes | 0 | 2 (100) | 2 (1) | |
| | | | | |
| **Migrant** | | | | |
| No | 76 (35) | 143 (65) | 219 (99) | 0.35 [b] |
| Yes | 1 (100) | 0 | 1 (1) | |
| | | | | |
| **Prostitution** | | | | |
| No | 75 (35) | 142 (65) | 217 (99) | 0.28 [b] |
| Yes | 2 (67) | 1 (33) | 3 (1) | |
| **Clinical Characteristics** | | | | |
| Site of TB | | | | |
| Extra-Pulmonary | 6 (46) | 7 (54) | 13 (6) | 0.38 [b] |
| Pulmonary | 68 (34) | 134 (66) | 202 (92) | |
| Missing | 3 | 2 | 5 (2) | |
| Previous TB treatment | 34 (43) | 45 (57) | 79 (36) | 0.34 [b] |
| New Case | 15 (28) | 38 (72) | 53 (24) | |
| Failure | 24 (31) | 53 (69) | 77 (35) | |
| Relapse | 2 (40) | 3 (60) | 5 (2) | |
| Treatment interrupted | 1 (50) | 1 (50) | 2 (1) | |
| Unknown | 1 | 3 | 4 (2) | |
| Previous TB treatment | 34 (43) | 45 (57) | 79 (36) | 0.07 |
| New Case | 42 (30) | 95 (70) | 137 (62) | |
| Retreatment Case | 1 | 3 | 4 (2) | |
| HIV clinical stage | | | | |
| Stage 3 | 47 (36) | 84 (64) | 131 (60) | 0.41 |
| Stage 4 | 24 (30) | 55 (70) | 79 (36) | |
| Missing | 6 | 4 | 10 (4) | |
| HIV treatment | | | | |
| No | 10 (91) | 1 (9) | 11 (5) | **< 0.01** [b] |
| Yes | 67 (32) | 142 (68) | 209 (95) | |

| Participant Characteristics | Adverse Treatment outcome N= 77 (35%) | Favorable Treatment Outcome N= 143 (65%) | Total N= 220 | P value * |
|---|---|---|---|---|
| Cotrimoxazole prophylaxis at enrollment | | | | |
| No | 9 (29) | 22 (71) | 31 (14) | 0.48 |
| Yes | 63 (36) | 114 (64) | 177 (80) | |
| Missing | 5 | 7 | 12 (6) | |
| BMI | | | | |
| Median (IQR) (N = 186) | 17.1 (15.6 – 18.8) | 17 (15.4 – 18.5) | 17.05 (15.4 – 18.6) | 0.77 [a] |
| Clinical Symptoms | | | | |
| Fever | | | | |
| No | 40 (32) | 85 (68) | 125 (57) | 0.28 |
| Yes | 37 (39) | 58 (61) | 95 (43) | |
| Sweat | | | | |
| No | 58 (33) | 120 (67) | 178 (81) | 0.12 |
| Yes | 19 (45) | 23 (55) | 42 (19) | |
| Dry cough | | | | |
| No | 68 (35) | 127 (65) | 195 (87) | 0.91 |
| Yes | 9 (36) | 16 (64) | 25 (13) | |
| Productive cough | | | | |
| No | 50 (38) | 80 (62) | 130 (59) | 0.20 |
| Yes | 27 (30) | 63 (70) | 90 (41) | |
| Blood spitting | | | | |
| No | 73 (34) | 141 (64) | 214 (97) | 0.19 [b] |
| Yes | 4 (67) | 2 (33) | 6 (3) | |
| Chest Pain | | | | |
| No | 66 (35) | 122 (65) | 188 (85) | 0.94 |
| Yes | 11 (34) | 21 (66) | 32 (15) | |
| Loss of Appetite | | | | |
| No | 51 (37) | 86 (63) | 137 (62) | 0.37 |
| Yes | 26 (31) | 57 (69) | 83 (38) | |
| Weight Loss | | | | |
| No | 50 (37) | 87 (63) | 137 (62) | 0.55 |
| Yes | 27 (33) | 56 (67) | 83 (83) | |

42

| Participant Characteristics | Adverse Treatment outcome N= 77 (35%) | Favorable Treatment Outcome N= 143 (65%) | Total N= 220 | P value * |
|---|---|---|---|---|
| Dyspnea | | | | |
| No | 62 (38) | 101 (62) | 163 (74) | 0.11 |
| Yes | 15 (26) | 42 (74) | 57 (26) | |
| **Laboratory Characteristics** | | | | |
| Smear result | | | | |
| Not conclusive | 1 (17) | 5 (83) | 6 (3) | 0.42 [b] |
| Negative | 28 (39) | 44 (61) | 72 (33) | |
| Positive | 41 (32) | 89 (68) | 130 (59) | |
| Missing | 7 | 5 | 12 (5) | |
| Smear result | | | | |
| Negative & non-conclusive | 36 (40) | 54 (60) | 90 (41) | 0.20 |
| Positive | 41 (32) | 89 (68) | 130 (59) | |
| CD4 count (cells/µL) | | | | |
| Median (IQR) (N = 120) | 138.5 (64 – 256) | 173.5 (83 – 365) | 161 (73 – 296) | 0.41 [a] |
| ALT (IU/L) | | | | |
| Median (IQR) (N = 93) | 21.3 (18.2 – 30.8) | 28 (18.5 – 42.55) | 26 (18.2 – 40.4) | 0.20 [a] |

Abbreviation: IQR – interquartile range, BMI – Body Mass Index, ALT – alanine aminotransferase, MDRTB – Multidrug-resistant Tuberculosis

* chi-square test with 2-sided probability

a Wilcoxon Scores (Rank Sums)

b Fisher's Exact Test

Table 3.3: Association between HCV and adverse MDR-TB treatment outcomes, multivariate analysis (N=220)

| Participant Characteristics | Adverse Treatment Crude OR (95%CI) | Model 1 Adjusted OR (95%CI) | Model 2 Adjusted OR (95%CI) | Model 3 Adjusted OR (95%CI) |
|---|---|---|---|---|
| Hepatitis C | | | | |
| Negative | 1 | 1 | 1 | 1 |
| Positive | 1.33 (0.49 – 3.65) | 1.31 (0.47 – 3.61) | 1.43 (0.50 – 4.03) | 1.28 (0.25 – 6.50) |

Model 1 adjusted for age and gender
Model 2 adjusted for age, gender, smear result, and history of previous TB treatment
Model 3 adjusted for age, gender, and illicit drug use

Figure 4.1 Participant selection of the study